VIDEO: 36-month Yutiq data released
VANCOUVER, British Columbia — EyePoint Pharmaceuticals CEO Nancy Lurker discusses 36-month safety and efficacy data for Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), released at the Association for Research in Vision and Ophthalmology meeting here.
The uveitis recurrence rate was 56.3% in Yutiq-treated eyes compared with 92.9% in sham-treated eyes. Eyes treated with Yutiq needed adjunctive intraocular or periocular medications 19.5% of the time, whereas 69% of sham-treated eyes needed rescue.
Disclosure: Lurker reports she is CEO of EyePoint Pharmaceuticals.